Business
Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement
(TheNewswire) Calgary, Canada – TheNewswire - March 4, 2024 - Voyageur P...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Canada –\n \n \n TheNewswire -\n \n \n March 4, 2024 -\n \n \n Voyageur Pharmaceuticals Ltd\n \n \n . (TSX.V: VM) (USA: VYYRF) (\"Voyageur\" or the\n\"Corporation\") and\n \n \n Applied Pharmaceutical Innovation\n \n \n (API), a\nleading industry-funded not-for-profit organization driving life\nsciences commercialization, proudly announce the signing of a Master\nServices Agreement (\n \n \n MSA\n \n \n ). This collaboration represents a\nsignificant advancement in both entities’ commitment to innovation,\nheralding a transformative step forward for Canada’s thriving life\nsciences sector.\n \n \n \n \n Under this strategic agreement, API will play a crucial\nrole in accelerating Voyageur’s imaging contrast medium product\ndevelopment, manufacturing, and commercialization. Leveraging API’s\nscientific and pharmaceutical expertise, the collaboration aims to\nfacilitate regulatory approvals and expedite the market entry of\nVoyageur’s contrast imaging products.\n \n \n \n \n This partnership will strategically target FDA, Health\nCanada and other regulatory agencies, by licensing across several key\ndevelopment areas:\n \n \n \n \n \n \n Accelerating the development and\nregistration of the innovative V@C60 MRI drug\n \n \n (Vanadium Fullerene Molecule for magnetic resonance imaging\n \n \n \n https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium-fullerene-molecule/\n \n \n \n \n \n \n \n Developing novel fullerene imaging\nproducts for targeted drug delivery within the body, with a focus on\napplications in Oncology.\n \n \n \n \n \n \n Introducing an advanced suite of new\nbarium contrast media products, with the goal to displace current\nproducts in the market.\n \n \n \n \n \n \n Expanding Voyageur’s Iodine\ncontrast media product pipeline, including potential development of\nfullerene iodine products\n \n \n \n \n \n \n Developing a carbon 60 based\nnutraceutical health supplement\n \n \n \n \n \n \n \"We are thrilled to embark on this groundbreaking\ncollaboration with Voya...